Literature DB >> 25789840

Adding bevacizumab to chemotherapy effectively control radioresistant brain metastases in ALK-positive lung adenocarcinoma.

Yu-Li Su1, Kun-Ming Rau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25789840     DOI: 10.1097/JTO.0000000000000449

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

1.  Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.

Authors:  Zhichao Liu; Youting Bao; Butuo Li; Xindong Sun; Linlin Wang
Journal:  Clin Transl Med       Date:  2018-01-09

Review 2.  Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.

Authors:  Ana P S Silva; Priscila V Coelho; Maristella Anazetti; Patricia U Simioni
Journal:  Hum Vaccin Immunother       Date:  2016-11-10       Impact factor: 3.452

3.  Long Noncoding RNA CRNDE/PRC2 Participated in the Radiotherapy Resistance of Human Lung Adenocarcinoma Through Targeting p21 Expression.

Authors:  Ming Zhang; Change Gao; Yi Yang; Gaofeng Li; Jian Dong; Yiqin Ai; Nan Chen; Wenhui Li
Journal:  Oncol Res       Date:  2017-05-17       Impact factor: 5.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.